Bionomics Limited announced that Spyridon “Spyros” Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and presenting two posters about BNC210 as a potential treatment for social anxiety disorder and post-traumatic stress disorder at the 2024 American Society of Clinical Psychopharmacology Annual Meeting taking place May 28 – 31 in Miami Beach, Florida.
ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon “Spyros” Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and presenting two posters about BNC210 as a potential treatment for social anxiety disorder and post-traumatic stress disorder (PTSD) at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place May 28 – 31 in Miami Beach, Florida. Details of the presentations are as follows:
Presentation title: Positive Results Achieved in a Phase 2b, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Treatment of PTSD (ATTUNE)
Session: Pharmaceutical Pipeline
Date and time: Tuesday, May 28 at 2:40 – 2:50 PM ET
Location: Loews Miami Beach Hotel, Salon 3
Presentation title: A Phase 3, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Acute Treatment of Anxiety in Social Anxiety Disorder (AFFIRM-1)
Poster Session: I
Date and time: Wednesday, May 29 at 11:15 AM – 1:00 PM ET
Location: Loews Miami Beach Hotel, Salon 4
Presentation title: Positive Results Achieved in a Phase 2b, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Treatment of PTSD (ATTUNE).
Poster Session: II
Date and time: Thursday, May 30 at 12:30 – 2:15 PM ET
Location: Loews Miami Beach Hotel, Salon 4
The poster presentations will be available on Bionomics’ website under the “Papers and Posters” page.
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Rajeev Chandra Company Secretary CoSec@bionomics.com.au | Investor Relations Kevin Gardner kgardner@lifesciadvisors.com | Investor Relations Chris Calabrese ccalabrese@lifesciadvisors.com |
About Bionomics Limited
Bionomics (NASDAQ:BNOX) is a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au
Forward-Looking Statements
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company’s plans to advance the development of its product candidates, the timing of achieving any development or regulatory milestones, and the comparability and potential of such product candidates, including to achieve any benefit or profile or any product approval or be effective. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including, but not limited to, the Company’s Annual Report on Form 20-F filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included in Bionomics’ filings with the SEC which are available from the SEC’s website (www.sec.gov) and on Bionomics’ website (www.bionomics.com.au) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
